South & Central America Breast Cancer Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Therapy, Breast Cancer Type, and Distribution Channel

Description

List of Tables

The South & Central America breast cancer therapeutics market was valued at US$ 1,530.71 million in 2022 and is expected to reach US$ 2,953.26 million by 2030; it is estimated to grow at a CAGR of 8.6% from 2022 to 2030.

Increasing Use of Personalized Medicine Fuels, the South & Central America Breast Cancer Therapeutics Market

Personalized medicine involves tailoring treatment plans to individual patients on the basis of their genetic makeup, among other factors. This approach allows for highly targeted and effective treatments, as it considers the unique characteristics of each patients cancer. Advancements in genomics and molecular diagnostics have made personalized medicine a viable option in breast cancer treatment. Healthcare providers can identify specific genetic mutations or biomarkers driving the cancers growth by analyzing a patients tumor at a molecular level. This information can then be used to select the most appropriate treatment options, such as targeted therapies or immunotherapies, that are likely to be the most effective for that particular patient. The use of personalized medicine in breast cancer therapeutics has the potential to significantly improve patient outcomes. For instance, in February 2022, NIH researchers developed a personalized breast cancer therapy approach, an experimental form of immunotherapy that uses a patients tumor-fighting immune cells to treat those with metastatic breast cancer, advancing personalized medicine.

South & Central America Breast Cancer Therapeutics Market Overview

The breast cancer therapeutics market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil is expected to have a major share in this region. It is also projected to grow at the highest growth rate. Increasing prevalence of breast cancer, aging population, and rise in per capita health care spending are among the factors that are expected to propel the breast cancer therapeutics market rapidly.

The increasing prevalence of breast cancer in Brazil drives the demand for breast cancer therapeutics. Breast cancer is the most prevalent malignancy in women in Brazil, according to Nature Publications. According to the Brazilian National Cancer Institute (INCA), approximately 66,200 new cases of breast cancer in women are identified in Brazil annually, translating to an age-standardized incidence rate of 43.74/100,000 women.

Improving healthcare infrastructure and access to advanced medical technologies in Brazil also drive the market. The government has been investing in expanding healthcare facilities and improving access to healthcare services, including breast cancer screening and treatment. This has led to early detection of breast cancer cases and increased the demand for therapeutics. Thus, the growing prevalence of breast cancer, improving healthcare infrastructure, and rising breast cancer awareness are key factors driving the breast cancer therapeutics market in Brazil.

South & Central America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Breast Cancer Therapeutics Market Segmentation

The South & Central America breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.

Based on drug therapy, the South & Central America breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the South & Central America breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.

By distribution channel, the South & Central America breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.

Based on country, the South & Central America breast cancer therapeutics market is categorized into Brazil, Argentina, the Rest of South & Central America. Brazil dominated the South & Central America breast cancer therapeutics market in 2022.

Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the South & Central America breast cancer therapeutics market.

Product Code: BMIRE00029751

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. South & Central America Breast Cancer Therapeutics Market - Key Industry Dynamics

4.1 Key Market Drivers
- 4.1.1 Growing Burden of Breast Cancer
- 4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
- 4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
- 4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:

5. Breast Cancer Therapeutics Market - South & Central America Market Analysis

5.1 South & Central America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030

6. South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy

6.1 Overview
6.2 South & Central America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
- 6.3.1 Overview
- 6.3.2 Targeted Drug Therapy: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.1 South & Central America Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
- 6.4.1 Overview
- 6.4.2 Hormonal Drug Therapy: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.4.2.1 South & Central America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
- 6.5.1 Overview
- 6.5.2 Chemotherapy: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
- 6.6.1 Overview
- 6.6.2 Immunotherapy/ Biological Therapy: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type

7.1 Overview
7.2 South & Central America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
- 7.3.1 Overview
- 7.3.2 Hormone Receptor: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
- 7.4.1 Overview
- 7.4.2 HER2+: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
- 7.5.1 Overview
- 7.5.2 Triple-Negative Breast Cancer: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 South & Central America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Drug Store and Retail Pharmacies: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
- 8.5.1 Overview
- 8.5.2 Online Pharmacies: South & Central America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. South & Central America Breast Cancer Therapeutics Market -Country Analysis

9.1 South & Central America Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
- 9.1.1 Overview
- 9.1.2 South & Central America Breast Cancer Therapeutics Market, Breakdown, by Country -Revenue (2022) (US$ Million)
- 9.1.3 South & Central America Breast Cancer Therapeutics Market, By Countries, 2022 and 2030 (%)
  - 9.1.3.1 Brazil
    - 9.1.3.1.1 Brazil Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.1.2 Brazil: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.1.2.1 Brazil: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.1.2.2 Brazil: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.1.3 Brazil: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.1.4 Brazil: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.2 Argentina
    - 9.1.3.2.1 Argentina Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.2.2 Argentina: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.2.2.1 Argentina: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.2.2.2 Argentina: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.2.3 Argentina: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.2.4 Argentina: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.3 Rest of South & Central America
    - 9.1.3.3.1 Rest of South & Central America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.3.2 Rest of South & Central America: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.3.2.1 Rest of South & Central America: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.3.2.2 Rest of South & Central America: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.3.3 Rest of South & Central America: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.3.4 Rest of South & Central America: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Breast Cancer Therapeutics Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Eli Lilly and Co
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Eisai Co Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Novartis AG
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 AstraZeneca Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Pfizer Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Gilead Sciences Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Merck & Co Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Amgen Inc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms